Paul Garabelli, MD
Clinical Cardiac Electrophysiology · Oklahoma City, OKNPI 1831344662
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (42.4%), travel and lodging and speaking fees — rather than concentrated in one kind of arrangement. 26 manufacturers reported payments, led by Medtronic at 55.3% of the total. Reporting peaked in 2019 at $7,669 and has fallen 71.6% since, to $2,179 in 2025.
Across 461 payments — averaging $70.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$18K
- Abbott$4K
- Boston Scientific$3K
- Atricure, Inc.$3K
- Philips North America LLC$2K
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$416
- plus $2K from 20 others
Across 28 payments — averaging $3071.72 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Abbott$86K
What the payments were for
- Speaking & faculty fees$6,75021%
- Travel & lodging$11,96937%
- Food & beverage$13,80542%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 141 | $17,977 |
| Abbott | 94 | $4,414 |
| Boston Scientific | 71 | $2,855 |
| Atricure, Inc. | 20 | $2,687 |
| Philips North America LLC | 18 | $1,894 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 23 | $416 |
| Impulse Dynamics (USA) Inc. | 6 | $403 |
| E.r. Squibb & Sons, L.L.C. | 14 | $342 |
| Pfizer | 18 | $322 |
| Johnson & Johnson | 18 | $299 |
| Biosense Webster, Inc. | 3 | $161 |
| AstraZeneca | 1 | $125 |
| Irhythm Technologies, Inc. | 7 | $121 |
| Novartis | 6 | $104 |
| Sanofi-aventis U.S. LLC | 5 | $94 |
| Boehringer Ingelheim | 3 | $54 |
| Baxter Healthcare | 1 | $48 |
| Kiniksa Pharmaceuticals International, PLC | 2 | $41 |
| Kestra Medical Technology Services, Inc. | 2 | $38 |
| Merck | 2 | $35 |
| Novo Nordisk | 1 | $19 |
| Scpharmaceuticals Inc. | 1 | $17 |
| Amarin Pharma, Inc. | 1 | $16 |
| Cook Medical LLC | 1 | $16 |
| Actelion Pharmaceuticals US, Inc. | 1 | $14 |
| Bayer | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Micra$2,728
- EPI-SENSE GUIDED COAGULATION SYSTEM WITH VISITRAX$2,122
- EVERA MRI XT DR SURESCAN$1,367
- (9520) IGT Devices Undivided$1,005
- Arctic Front$871
- EnSite Precision Cardiac Mapping System$841
- Watchman$746
- IGT Devices Und$603
- OPTIMIZER$592
- ENSITE$549
- TACTICATH ABLATION CATHETER, SENSOR ENABLED$334
- ENSITE PRECISION$332
- VANTAGEVIEW$304
- SelectSecure$252
- NA$240
- ELIQUIS$232
- LINQ II$227
- Ensite Cardiac Mapping System$168
- AZURE XT DR MRI SURESCAN$153
- ARCTIC FRONT ADVANCE$144
How this compares
$32,524 in reported general payments places this provider in the 70th percentile of 30 clinical cardiac electrophysiology providers in Oklahoma.
See all clinical cardiac electrophysiology providers in Oklahoma →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 618 | $568,834 |
| XareltoRivaroxaban | 127 | $153,416 |
| EntrestoSacubitril/Valsartan | 109 | $117,532 |
| Dofetilide | 246 | $27,777 |
| JardianceEmpagliflozin | 14 | $25,267 |
| FarxigaDapagliflozin Propanediol | 22 | $13,479 |
| Flecainide Acetate | 203 | $7,777 |
| Metoprolol Succinate | 436 | $7,584 |
| Carvedilol | 385 | $4,483 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 154 | $4,270 |
| SotalolSotalol Hcl | 182 | $4,087 |
| Diltiazem 24hr Er (La)Diltiazem Hcl | 32 | $3,684 |
| Mexiletine Hcl | 40 | $3,250 |
| Potassium Chloride | 194 | $2,849 |
| Amiodarone Hcl | 177 | $2,490 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $322 | $568,834618 claims |
| Johnson & JohnsonXarelto | $299 | $153,416127 claims |
| NovartisEntresto | $104 | $117,532109 claims |
| Boehringer IngelheimJardiance | $54 | $25,26714 claims |
| AstraZenecaFarxiga | $125 | $13,47922 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 30 clinical cardiac electrophysiology providers in Oklahoma.
Other clinical cardiac electrophysiology in Oklahoma City
- Warren JackmanOklahoma City$2.3M
- Sunny PoOklahoma City$260K
- John SummersOklahoma City$135K
- Sean HalleranOklahoma City$105K
- Ian ParkerOklahoma City$74K
- Coty JewellOklahoma City$24K
- Krittapoom AkrawinthawongOklahoma City$24K
- Charles TeOklahoma City$21K
- Terrance KhastgirOklahoma City$19K
- Cliona MurphyOklahoma City$18K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.